Ulcerative Colitis Treatment Trends & KOL Insights

About the Study

Study Objective

This ulcerative colitis treatment market insights study evaluates KOL perceptions regarding current and emerging treatment options for moderate-to-severe Ulcerative Colitis, including prescribing preferences, unmet needs, barriers to adoption, physician perception of UC therapies, and future expectations across the US and Europe. The study was developed using insights methodologies supported by KOL Atlas, a healthcare KOL insights platform for pharma and biotech market intelligence.

Sample Composition

US respondents: 25
EU5 respondents: 25
Total respondents: 50

Expected Deliverables

US vs EU comparison
Therapy preference mapping
Unmet needs analysis
Innovation perception assessment
Adoption barrier analysis
Future outlook (3–5 years)

Detailed Findings

Question-by-Question Results

Question 01

Approximately how many moderate-to-severe UC patients do you manage monthly?

<20 patients 10%

20–50 patients 34%

51–100 patients 38%

>100 patients 18%

Patient volume segmentation and KOL experience level in moderate-to-severe ulcerative colitis treatment trends.
The findings reflect strong physician experience in inflammatory bowel disease treatment trends and physician prescribing behavior.

Question 02

Which therapy classes do you prescribe most frequently for moderate-to-severe UC? (Select Top 3)

Anti-TNF biologics 78%

JAK inhibitors 56%

IL-23 inhibitors 48%

Integrin inhibitors 42%

S1P modulators 30%

Corticosteroids 26%

Immunomodulators 22%

The data highlights gastroenterologist prescribing trends UC and growing interest in biologics for ulcerative colitis treatment and emerging mechanisms in ulcerative colitis treatment. Similar physician interest in innovative therapeutic approaches was also observed in this microbiome therapy KOL study focused on emerging microbiome-based therapies.

Question 03

Overall, how satisfied are you with currently available UC therapies in achieving long-term remission?

Very satisfied 12%

Satisfied 46%

Neutral 28%

Dissatisfied 12%

Very dissatisfied 2%

Results indicate ongoing long-term remission challenges in ulcerative colitis despite recent innovation in advanced biologics and oral small molecules.

Question 04

What are the biggest unmet needs in current UC management? (Select Top 3)

Durable remission 74%

Steroid-free remission 66%

Better safety profile 58%

Faster onset of action 44%

Improved mucosal healing 42%

Personalized treatment selection 36%

Oral treatment convenience 24%

The findings reinforce the importance of treatment optimization, personalized treatment selection, biomarker-guided therapy, and patient-centric treatment approaches.

Question 05

Which factors most influence your therapy selection decisions in UC?

Clinical efficacy 92%

Safety / tolerability 88%

Long-term remission data 72%

Speed of symptom relief 56%

Payer / access restrictions 52%

Patient preference 46%

Route of administration 34%

Clinical efficacy, safety profile, payer access, and treatment persistence remain key considerations in ulcerative colitis therapy preferences.

Question 06

How do you perceive newer mechanisms (e.g., JAK inhibitors, IL-23 inhibitors, S1P modulators) versus traditional biologics?

Significantly better 22%

Moderately better 48%

Similar 22%

Worse 8%

The results suggest increasing confidence in JAK inhibitor adoption in UC and future growth of IL-23 inhibitors in UC treatment. Comparable innovation perception trends were identified in this metabolic disease KOL insights study evaluating physician adoption of emerging therapies across chronic disease management.

Question 08

What are the major barriers limiting broader adoption of newer UC therapies?

1

Safety concerns

68%

2

Lack of long-term data

62%

3

Payer / access restrictions

54%

4

Cost burden

48%

5

Monitoring requirements

34%

6

Limited differentiation

26%

Question 07

At what stage do you typically introduce advanced therapies in UC treatment?

38%

Early use (1st biologic line)

44%

After anti-TNF failure

14%

Refractory / severe only

4%

Highly selective use

Key Insights

The study highlights evolving treatment escalation strategies and increasing adoption of advanced therapies in ulcerative colitis.
The findings emphasize payer restrictions impact on UC therapy adoption and concerns surrounding long-term efficacy and therapy differentiation.

Decision Driver	% Rating Highly Important
Clinical efficacy	92%
Safety / tolerability	88%
Long-term remission data	72%
Speed of symptom relief	56%
Payer / access restrictions	52%
Patient preference	46%
Route of administration	34%

Question 09

Which therapy class do you expect to show the highest growth in UC treatment over the next 3–5 years?

Expected Growth Over Next 3–5 Years

IL-23 inhibitors expected to lead market expansion in UC treatment

KOL perception on IL-23 inhibitors in ulcerative colitis remains highly positive, supporting expectations for continued market expansion and innovation perception assessment. These findings demonstrate the growing importance of real-time physician intelligence platforms such as KOL Atlas for tracking evolving therapy adoption trends.

42%

IL-23 inhibitors

30%

JAK inhibitors

14%

S1P modulators

82%

of KOLs cite durable long-term
remission as ideal therapy attribute

Question 10 — What attributes would define an ideal future UC therapy? (Select Top 3)

Durable long-term remission 82%

Excellent safety profile 76%

Rapid onset 54%

Steroid-free control 52%

Personalized biomarker guidance 38%

Convenient oral dosing 34%

Minimal monitoring 22%

Physicians continue to prioritize durable remission in UC treatment, rapid symptom relief, safety profile improvements, and personalized medicine approaches.

Synthesis

Expected Study Deliverables

US vs EU Comparison

Regional differences in prescribing and perceptions

Therapy Preference Mapping

Most preferred current and future classes

Unmet Needs Analysis

Ranked unmet needs in UC management

Innovation Perception Assessment

Acceptance of emerging mechanisms

Adoption Barrier Analysis

Commercial and clinical access challenges

Future Outlook

Expected market evolution over 3–5 years

This ulcerative colitis market research study provides actionable gastroenterology physician insights report findings for pharma, biotech, and healthcare stakeholders evaluating ulcerative colitis competitive landscape analysis and biologic market assessment UC opportunities.

FAQ

Frequently Asked Questions

What therapies are most prescribed for ulcerative colitis?

According to this ulcerative colitis physician survey, Anti-TNF biologics remain the most prescribed therapies for moderate-to-severe ulcerative colitis treatment, followed by JAK inhibitors and IL-23 inhibitors. The study highlights strong biologic adoption in ulcerative colitis and increasing physician interest in advanced therapies in ulcerative colitis due to improved clinical efficacy and long-term remission potential. Related prescribing pattern analysis can also be explored through our KOL Atlas platform

Why are physicians interested in IL-23 inhibitors?

Physicians view IL-23 inhibitors as one of the most promising new treatments for ulcerative colitis because of their potential to deliver durable remission, improved safety profiles, and better treatment persistence. The findings also show positive KOL perception on IL-23 inhibitors in ulcerative colitis and strong future growth expectations within the UC treatment landscape.

What are the main barriers to advanced UC therapy adoption?

The major barriers limiting advanced UC therapy adoption include safety concerns, lack of long-term efficacy data, payer access restrictions, monitoring requirements, and treatment cost burden. These barriers significantly influence physician prescribing behavior and treatment optimization strategies in moderate-to-severe ulcerative colitis treatment trends.

How do physicians evaluate long-term remission in UC?

Physicians evaluate long-term remission in ulcerative colitis treatment using multiple factors including clinical efficacy, mucosal healing, steroid-free remission, treatment persistence, and patient quality of life. Durable remission remains one of the biggest UC therapy unmet needs identified in this gastroenterology market intelligence study.

What future therapies could transform ulcerative colitis treatment?

Emerging mechanisms such as IL-23 inhibitors, JAK inhibitors, S1P modulators, and future cell/gene therapies are expected to transform the future of ulcerative colitis treatment. Similar innovation-focused physician perception trends were also identified in our microbiome therapy perception study.